| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals
|
Nov 11, 2025 | BUY |
Strong Buy
+808.6% avg upside
19 analysts
|
$13.00
1060.71% Upside
|
-45.0% |
|
BNTX
BioNTech SE
|
Jun 02, 2025 | HOLD |
Strong Buy
+51.1% avg upside
26 analysts
|
— | -21.2% |
|
GILD
Gilead Sciences
|
Aug 09, 2024 | BUY |
Strong Buy
-5.3% avg upside
66 analysts
|
$95.00
23.77% Downside
|
+67.3% |
|
SRPT
Sarepta Therapeutics
|
Jun 21, 2024 | BUY |
Buy
+241.4% avg upside
49 analysts
|
$215.00
1094.52% Upside
|
-87.5% |
|
SPRB
Spruce Biosciences
|
Jun 13, 2024 | BUY |
Strong Buy
+84.9% avg upside
14 analysts
|
$3.00
94.56% Downside
|
-88.8% |
|
CLLS
Cellectis SA
|
Jun 12, 2024 | BUY |
Strong Buy
+603.6% avg upside
16 analysts
|
$10.00
255.96% Upside
|
-43.5% |
|
MRNA
Moderna
|
Jun 12, 2024 | BUY |
Hold
+15.8% avg upside
38 analysts
|
$179.00
199.07% Upside
|
-81.5% |
|
BMEA
Biomea Fusion
|
Jun 07, 2024 | BUY |
Strong Buy
+976.5% avg upside
15 analysts
|
$60.00
4624.46% Upside
|
-39.9% |
|
ALLO
Allogene Therapeutics
|
May 21, 2024 | BUY |
Strong Buy
+634.9% avg upside
28 analysts
|
$13.00
516.14% Upside
|
-58.7% |
|
PHAR
Pharming Group
|
May 14, 2024 | BUY |
Strong Buy
+199.7% avg upside
4 analysts
|
$40.00
213.82% Upside
|
-5.0% |
|
VRTX
Vertex Pharmaceuticals
|
May 10, 2024 | BUY |
Strong Buy
-4.8% avg upside
61 analysts
|
$500.00
7.57% Upside
|
+0.5% |
|
UTHR
United Therapeutics
|
May 09, 2024 | BUY |
Strong Buy
-18.9% avg upside
26 analysts
|
$400.00
25.88% Downside
|
+13.3% |
|
REGN
Regeneron
|
May 03, 2024 | BUY |
Strong Buy
+26.8% avg upside
57 analysts
|
$1175.00
93.42% Upside
|
-36.6% |
|
OPTEY
Opthea Limited Sponsored ADR
|
Apr 25, 2024 | BUY |
Buy
+37213.4% avg upside
7 analysts
|
$18.00
89452.17% Upside
|
· |
|
GANX
Gain Therapeutics
|
Apr 23, 2024 | BUY |
Strong Buy
+321.1% avg upside
9 analysts
|
$9.00
373.70% Upside
|
-45.4% |
|
PHVS
Pharvaris
|
Mar 13, 2024 | BUY |
Strong Buy
+36.7% avg upside
14 analysts
|
$36.00
8.81% Upside
|
-28.0% |
|
TRDA
Entrada Therapeutics Inc
|
Jan 05, 2024 | BUY |
Strong Buy
+199.6% avg upside
10 analysts
|
$22.00
214.20% Upside
|
+20.1% |
|
ATYR
aTyr Pharma
|
Nov 22, 2023 | HOLD |
Buy
+1956.5% avg upside
17 analysts
|
— | +159.0% |
|
ELOX
Eloxx Pharmaceuticals
|
Nov 02, 2023 | BUY |
Strong Buy
+157.3% avg upside
8 analysts
|
$30.00
116.89% Upside
|
· |
|
FR:ALCOX
Nicox SA
|
Jan 22, 2021 | HOLD |
Buy
+1630.4% avg upside
5 analysts
|
— | · |
|
IMNN
Imunon
|
Nov 16, 2020 | HOLD |
Buy
+716.3% avg upside
11 analysts
|
— | +52.8% |
|
AU:OPT
Opthea
|
Nov 11, 2020 | BUY |
Strong Buy
+2166.6% avg upside
4 analysts
|
$51.30
8449.96% Upside
|
· |
|
NL:PHARM
Pharming Group
|
Oct 29, 2020 | BUY |
Strong Buy
+190.5% avg upside
4 analysts
|
$3.50
208.39% Upside
|
· |
|
SMMT
Summit Therapeutics
|
Jun 05, 2020 | HOLD |
Strong Buy
+107.5% avg upside
27 analysts
|
— | +127.3% |
|
SLS
SELLAS Life Sciences Group
|
Apr 03, 2019 | BUY |
Strong Buy
+707.4% avg upside
15 analysts
|
$650.00
7392.76% Upside
|
-96.9% |
|
ATNM
Actinium Pharmaceuticals
|
Mar 27, 2019 | BUY |
Strong Buy
+630.9% avg upside
11 analysts
|
$5.00
380.75% Upside
|
-58.0% |
|
PVLA
Palvella Therapeutics
|
Dec 31, 2018 | HOLD |
Strong Buy
+40.2% avg upside
27 analysts
|
— | · |
|
SNDX
Syndax Pharmaceuticals
|
Nov 23, 2018 | HOLD |
Strong Buy
+86.7% avg upside
27 analysts
|
— | · |
|
QURE
uniQure
|
Nov 24, 2017 | HOLD |
Strong Buy
+23.3% avg upside
29 analysts
|
— | +72.9% |
|
AFMDQ
Affimed
|
Nov 24, 2017 | HOLD |
Buy
+304698900.0% avg upside
15 analysts
|
— | · |
|
SYBX
Synlogic
|
Feb 03, 2017 | HOLD |
Buy
+3244.1% avg upside
11 analysts
|
— | -39.1% |
|
AMGN
Amgen
|
Feb 22, 2016 | SELL |
Buy
-12.8% avg upside
57 analysts
|
$135.00
60.80% Downside
|
-19.2% |
|
OCUL
Ocular Therapeutix
|
Oct 23, 2015 | BUY |
Strong Buy
+149.9% avg upside
21 analysts
|
$40.00
300.21% Upside
|
-4.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.